- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03547037
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
November 3, 2022 updated by: Janssen Pharmaceutical K.K.
A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers
The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).
Study Overview
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chuo-Ku, Japan, 104-0045
- National Cancer Center Hospital
-
Kashiwa, Japan, 277-8577
- National Cancer Center Hospital East
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Radiographically, histologically, or cytologically confirmed advanced or refractory solid tumor(s) that is metastatic or unresectable, and previously received or was ineligible for standard treatment options. Participants with solid tumor(s) for which anti-PD-1 or anti-PD-L1 antibody as a monotherapy is approved in Japan are eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Thyroid function laboratory values within normal range
- A woman must be: a) Not of childbearing potential; b) Of childbearing potential and practicing a highly effective, preferably user-independent method of contraception (failure rate of less than (<) 1 percent (%) per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study intervention and continue for 5 months following discontinuation of JNJ-63723283 or 3 months following discontinuation of erdafitinib, whichever is longer. Especially participants receiving erdafitinib must agree to use two contraceptive methods and one must be user-independent method; Examples of highly effective contraceptives include: user-independent methods: intrauterine device (IUD) or intrauterine contraceptive system (IUS) and user-dependent methods: combined (estrogen- and progestogen-containing) hormonal contraception or progesterone-containing hormonal contraception. c) Agree not to donate eggs (ova, oocytes), during the study and continue for 5 months following discontinuation of JNJ-63723283 or 3 months following discontinuation of erdafitinib, whichever is longer
- A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person and must agree not to donate sperm for 5 months following discontinuation of JNJ-63723283 or 5 months following discontinuation of erdafitinib, whichever is longer
Exclusion Criteria:
- Had prior treatment with an anti-PD-1 antibody, anti-PD-L1 antibody or anti-PDL2 antibody within 30 days of first study drug administration and/or has an ongoing Grade 2 or higher immunotherapy-related toxicity. If the subject has an experience of treatment with these agents, the subject must not have had severe immunotherapy-related toxicity
- History of or concurrent interstitial lung disease
- Active autoimmune disease or a documented history of autoimmune disease that requires systemic steroids or immunosuppressive agents
- Grade 3 or higher toxicity effects from previous treatment with immunotherapy
- Has taken immunosuppressive doses of systemic medications, such as corticosteroids doses greater than (>) 10 milligram per day (mg/day) prednisolone or equivalent), within 2 weeks before the planned first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase 1a: JNJ-63723283 (Monotherapy)
Participants will receive monotherapy of JNJ-63723283 intravenously.
The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
|
JNJ-63723283 will be administered intravenously.
Other Names:
|
EXPERIMENTAL: Phase 1b: Erdafitinib Combination
Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
|
JNJ-63723283 will be administered intravenously.
Other Names:
Erdafitinib will be administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a and Phase 1b: Number of Participants with Dose Limiting Toxicity (DLT)
Time Frame: Up to 6 weeks (maximum)
|
The DLTs are based on drug-related adverse events and defined as any of the following events: Infusion-related reactions, non-hematologic toxicity of Grade 3 or higher, or certain hematologic toxicity.
|
Up to 6 weeks (maximum)
|
Phase 1a and Phase 1b: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Time Frame: Up to 6 weeks (maximum)
|
Severity of DLT will be graded by using NCI-CTCAE, version 4.03.
Severity scale ranges from Grade 1 to Grade 5 with Grades as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), and Grade 5 (Death).
|
Up to 6 weeks (maximum)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Number of Participants with Adverse Events and Immune-Related Adverse Event (irAE) by Severity
Time Frame: Approximately up to 3 years
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Severity of Adverse Event will be graded by using NCI-CTCAE, version 4.03.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death) with Grades as follows: Grade 1 (Mild) Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life threatening) and Grade 5 (Death).
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Number of Participants With Clinically Significant Changes in Vital Signs as a Measure of Safety and Tolerability
Time Frame: Approximately up to 3 years
|
Number of participants with clinically significant changes in the vital signs including blood pressure, pulse rate, and body temperature will be reported.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Number of Participants With Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability
Time Frame: Approximately up to 3 years
|
Number of participants with clinical laboratory abnormalities (clinical laboratory tests include the following: hematology panel, coagulation panel, serum chemistry panel, endocrine panel, serology and pregnancy test [women only]) will be reported.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Number of Participants With ECG Abnormalities as a Measure of Safety and Tolerability
Time Frame: Approximately up to 3 years
|
Number of participants with electrocardiogram (ECG) abnormalities will be reported.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Maximum Serum Concentration (Cmax) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
The Cmax is the maximum observed serum concentration.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Serum Concentration Immediately Prior to the Next Drug Administration (Ctrough) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
Ctrough is the serum concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Time to reach Maximum Observed serum Concentration (Tmax) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
The Tmax is defined as actual sampling time to reach maximum observed serum concentration.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Area Under the Serum Concentration-Time Curve Between 2 Defined Sampling Points, (t1 and t2) (AUC[t1-t2]) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
The AUC(t1-t2) is the area under the serum concentration-time curve between 2 defined sampling points, t1 and t2.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Elimination Half-Life (t1/2) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
T1/2 is the time measured for the serum concentration to decrease by 1 half to its original concentration.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Total Systemic Clearance (CL) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
CL is a quantitative measure of the rate at which JNJ-63723283 is removed from the body.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Volume of Distribution at Steady-State (Vss) of JNJ-63723283
Time Frame: Approximately up to 3 years
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
Steady state volume of distribution is the apparent volume of distribution at steady-state.
|
Approximately up to 3 years
|
Phase 1b: Cmax of Erdafitinib
Time Frame: Approximately up to 3 years
|
The Cmax is the maximum observed plasma concentration.
|
Approximately up to 3 years
|
Phase 1b: Ctrough of Erdafitinib
Time Frame: Approximately up to 3 years
|
Ctrough is the plasma concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.
|
Approximately up to 3 years
|
Phase 1a and Phase 1b: Number of Participants With Anti-JNJ 63723283 Antibodies
Time Frame: Approximately up to 3 years
|
Number of participants with anti-JNJ 63723283 antibodies will be assessed.
|
Approximately up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 31, 2018
Primary Completion (ACTUAL)
July 4, 2022
Study Completion (ACTUAL)
July 4, 2022
Study Registration Dates
First Submitted
May 24, 2018
First Submitted That Met QC Criteria
May 24, 2018
First Posted (ACTUAL)
June 6, 2018
Study Record Updates
Last Update Posted (ACTUAL)
November 7, 2022
Last Update Submitted That Met QC Criteria
November 3, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- CR108471
- 63723283LUC1002 (OTHER: Janssen Pharmaceutical K.K., Japan)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Ronald LevyBristol-Myers SquibbCompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid NeoplasmUnited States
-
Massachusetts General HospitalRecruitingMalignant Neoplasm | Benign NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
Clinical Trials on JNJ-63723283
-
Johnson & Johnson Enterprise Innovation Inc.RecruitingAdvanced Solid TumorsUnited States
-
Janssen Research & Development, LLCRecruitingUrinary Bladder NeoplasmsUnited States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Germany, Netherlands
-
Janssen Research & Development, LLCActive, not recruitingNeoplasmsUnited Kingdom, Spain, United States, Russian Federation, Poland, Sweden, Moldova, Republic of
-
Janssen Research & Development, LLCCompletedHepatitis B, ChronicFrance, Germany, Spain, Poland, Belgium
-
Janssen Research & Development, LLCRecruitingMetastatic Castration-resistant Prostate NeoplasmsUnited States, Australia
-
Janssen Research & Development, LLCRecruitingBladder CancerUnited States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCActive, not recruitingUrothelial CarcinomaFrance, United States, Korea, Republic of, Belgium, Poland, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus
-
Janssen Research & Development, LLCRecruitingCarcinoma, Non-Small-Cell LungKorea, Republic of, United States, Malaysia, Turkey
-
Rahul AggarwalJanssen Scientific Affairs, LLCActive, not recruitingProstate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine CarcinomaUnited States